Triple Drug Therapy for Relapsed Multiple Myeloma With Liver Issues
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study tests a combination of three cancer drugs (belantamab mafodotin, bortezomib, and dexamethasone) in people with multiple myeloma who have had prior treatment and moderate liver function problems. The goal is to see if this combination works safely in patients whose cancer has come back or worsened.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- Confirmed diagnosis of multiple myeloma that has grown after at least one prior treatment
- At least one measurable sign of disease (protein in urine/blood, bone marrow involvement, or tumor on imaging)
- Moderate liver impairment (specific blood test results required)
- No serious eye problems, active infections, or heart rhythm issues
- Willingness to use birth control and follow study procedures
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests different dosing schedules of three drugs (belantamab mafodotin, bortezomib, and dexamethasone) together to treat multiple myeloma that has come back or stopped responding to previous treatments. The goal is to find a dosing plan that works well and is tolerable for patients.
This trial tests a new drug called belantamab mafodotin (a targeted antibody therapy) combined with standard treatments for multiple myeloma that has come back or stopped responding. It looks at three different drug combinations to see which works best for people who have had 1 or 2 prior treatments.
This study tests the safety and effectiveness of the drug belantamab, alone or with other treatments, for people with multiple myeloma that has come back or stopped responding to previous treatments.
This trial tests a new drug combination (belantamab mafodotin plus lenalidomide and dexamethasone) against the usual treatment for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. It aims to see if the new combination works better.
This Phase 2 study tests a combination of medicines (isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone) for multiple myeloma that has come back or did not respond to prior treatment. It may help by better controlling the myeloma after standard therapies have failed.
This early-phase study tests whether adding belantamab mafodotin to a combination treatment (daratumumab, pomalidomide, and dexamethasone) is safe and can shrink multiple myeloma in people whose disease is back or not responding. It is for people who have only had one prior treatment and cannot respond to lenalidomide.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.